JBMR Plus
(Sep 2019)
Local Tumor Recurrence and Escape from Suppression of Bone Resorption With Denosumab Treatment in Two Adolescents With Giant Cell Tumors of Bone
- Umar Akel,
- Marie‐Eve Robinson,
- Joel Werier,
- Raja Rampersaud,
- Kawan Rakhra,
- Donna Johnston,
- Victor N Konji,
- Jinhui Ma,
- Marika Pagé,
- Mary Ann Matzinger,
- Leanne M Ward
Affiliations
- Umar Akel
- Pediatric Bone Health Clinical Research Program, Children's Hospital of Eastern Ontario Research Institute Ottawa Canada
- Marie‐Eve Robinson
- Pediatric Bone Health Clinical Research Program, Children's Hospital of Eastern Ontario Research Institute Ottawa Canada
- Joel Werier
- Department of Surgery Division of Orthopaedic Surgery, The Ottawa Hospital Ottawa Canada
- Raja Rampersaud
- Department of Surgery Division of Orthopaedics, University Health Network Toronto Canada
- Kawan Rakhra
- Department of Surgery Division of Orthopaedic Surgery, The Ottawa Hospital Ottawa Canada
- Donna Johnston
- Department of Pediatrics Division of Hematology/Oncology, Children's Hospital of Eastern Ontario Ottawa Canada
- Victor N Konji
- Pediatric Bone Health Clinical Research Program, Children's Hospital of Eastern Ontario Research Institute Ottawa Canada
- Jinhui Ma
- Department of Health Research Methods Evidence, and Impact, McMaster University Hamilton Canada
- Marika Pagé
- Pediatric Bone Health Clinical Research Program, Children's Hospital of Eastern Ontario Research Institute Ottawa Canada
- Mary Ann Matzinger
- Department of Diagnostic Imaging Children's Hospital of Eastern Ontario Ottawa Canada
- Leanne M Ward
- Pediatric Bone Health Clinical Research Program, Children's Hospital of Eastern Ontario Research Institute Ottawa Canada
- DOI
-
https://doi.org/10.1002/jbm4.10196
- Journal volume & issue
-
Vol. 3,
no. 9
pp.
n/a
– n/a
Abstract
Read online
ABSTRACT Giant cell tumors of bone (GCTB) may be difficult to resect because of size or location. We describe two adolescents who were treated with denosumab and followed for tumoral and biochemical responses. Denosumab was effective in achieving sufficient regression to allow surgical resection and in preserving peritumor cortical bone. Reactivation of bone resorption markers was noted while the patients were receiving monthly denosumab. One patient suffered a local tumor recurrence. Denosumab was safe in enabling surgical resection of GCTB. However, the effect was transient, with an escape of resorption markers and tumor recurrence. © 2019 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.
Keywords
WeChat QR code
